Overview

Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]

Status:
Completed

Trial end date:
2010-03-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this survey is to evaluate the safety (that is, frequency of adverse events) and efficacy (that is, hemostatic effect, rate of rebleeding after confirmation of hemostasis) of administration of lansoprazole intravenous 30 milligram (mg) (Takepron Intravenous 30 mg ) to a large number of participants with acute stress ulcer or acute gastric mucosal lesion in daily medical practice.

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Takeda

Treatments:

Dexlansoprazole
Lansoprazole

Criteria

Inclusion Criteria:

- Inclusion Criteria:

Participants with the following diseases for whom oral administration is not feasible:

Acute stress ulcer, and acute gastric mucosal lesions (both of which should be accompanied
by bleeding).

Exclusion Criteria:

-